Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia

University of California San Diego

Status and phase: Completed; Phase 4

Conditions: Healthy; Schizophrenia; Schizo Affective Disorder; Schizoaffective Disorder

Treatments: Drug: Memantine; Drug: Placebos

Study type: Interventional

Funder types: Other

Identifiers

NCT03860597

R01MH094320

Details and patient eligibility

About

This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fidelity (APF) and auditory learning.

Enrollment: 42 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• diagnosis of schizophrenia OR schizoaffective-depressed OR healthy subjects
• ages 18-50 for all subjects
• double barrier contraception for all subjects
• not pregnant for all subjects

Exclusion criteria

• DSM-IV Axis I or II Diagnosis for for healthy subjects
• MEM or amantadine for patients
• current substance abuse for all subjects
• current recreational drug use for all subjects
• history of other significant medical illness (e.g. cancer, diabetes, heart disease, HIV, seizures) for all subjects
• open head injury or closed head injury with loss of consciousness > 1 min for all subjects
• hearing or visual impairment for all subjects
• pregnancy for all subjects
• dementia for all subjects
• mental retardation for all subjects

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

42 participants in 2 patient groups, including a placebo group

Memantine

Active Comparator group

Treatment:

Drug: Memantine

Placebo

Placebo Comparator group

Treatment:

Drug: Placebos